retatrutide nejm 2023 obesity trial ly3437943 A study of Lilly's weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk This week's most cited articles:

This mechanism can temporarily disrupt menstrual regularity

This creates an elevated TIMP:MMP ratio that correlates with collagen and elastin synthesis stimulation

Transient Permeation Enhancer (TPE) technology for oral delivery of octreotide: a technological evaluation

Reconstituting the same 5 mg vial with 1 mL instead of 3 mL produces 5,000 mcg/mL, and 100 mcg then occupies 0.02 mL (2 units) rather than 0.06 mL (6 units)

Hospira, now part of Pfizer, is recognised globally as a trusted manufacturer of pharmaceutical injectables and critical care solutions

Section 1833(t)(17)(C)(i) of the Act also requires measures included in the Hospital OQR and ASCQR Programs to reflect consensus among affected parties